218 related articles for article (PubMed ID: 1819735)
1. Involvement of platelet-activating factor (PAF) in septic shock and priming as indicated by the effect of hetrazepinoic PAF antagonists.
Heuer HO
Lipids; 1991 Dec; 26(12):1369-73. PubMed ID: 1819735
[TBL] [Abstract][Full Text] [Related]
2. Platelet-activating factor antagonists in experimental shock.
Muacevic G; Heuer HO
Arzneimittelforschung; 1992 Aug; 42(8):1001-4. PubMed ID: 1418068
[TBL] [Abstract][Full Text] [Related]
3. PAF-induced amplification of mediator release in septic shock: prevention or downregulation by PAF antagonists.
Koltai M; Hosford D; Braquet P
J Lipid Mediat; 1993; 6(1-3):183-98. PubMed ID: 8357981
[No Abstract] [Full Text] [Related]
4. Role for intracellular platelet-activating factor in the circulatory failure in a model of gram-positive shock.
De Kimpe SJ; Thiemermann C; Vane JR
Br J Pharmacol; 1995 Dec; 116(8):3191-8. PubMed ID: 8719795
[TBL] [Abstract][Full Text] [Related]
5. A triazolodiazepine platelet activating factor receptor antagonist (WEB 2086) reduces pulmonary dysfunction during endotoxin shock in swine.
Siebeck M; Weipert J; Keser C; Kohl J; Spannagl M; Machleidt W; Schweiberer L
J Trauma; 1991 Jul; 31(7):942-9; discussion 949-50. PubMed ID: 1906548
[TBL] [Abstract][Full Text] [Related]
6. WEB 2347: pharmacology of a new very potent and long acting hetrazepinoic PAF-antagonist and its action in repeatedly sensitized guinea-pigs.
Heuer HO
J Lipid Mediat; 1991; 4(1):39-44. PubMed ID: 1893086
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologic activity of bepafant (WEB 2170), a new and selective hetrazepinoic antagonist of platelet activating factor.
Heuer HO; Casals-Stenzel J; Muacevic G; Weber KH
J Pharmacol Exp Ther; 1990 Dec; 255(3):962-8. PubMed ID: 2262914
[TBL] [Abstract][Full Text] [Related]
8. PAF-cytokine autocatalytic feed-back network in septic shock: involvement in acute renal failure.
Koltai M; Pirotzky E; Braquet P
Nephrol Dial Transplant; 1994; 9 Suppl 4():69-72. PubMed ID: 7800272
[No Abstract] [Full Text] [Related]
9. The pathophysiological role of PAF in anaphylactic lung reaction in the guinea pig and in endotoxin shock evidenced by the specific PAF-antagonist WEB 2086.
Heuer H; Casals-Stenzel J
Prog Clin Biol Res; 1989; 308():925-30. PubMed ID: 2675077
[No Abstract] [Full Text] [Related]
10. Protective effect of WEB 2086, a novel antagonist of platelet activating factor, in endotoxin shock.
Casals-Stenzel J
Eur J Pharmacol; 1987 Mar; 135(2):117-22. PubMed ID: 3582490
[TBL] [Abstract][Full Text] [Related]
11. Platelet-activating factor and arachidonic acid metabolites mediate tumor necrosis factor and eicosanoid kinetics and cardiopulmonary dysfunction during bacteremic shock.
Quinn JV; Slotman GJ
Crit Care Med; 1999 Nov; 27(11):2485-94. PubMed ID: 10579269
[TBL] [Abstract][Full Text] [Related]
12. Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats.
Qi M; Jones SB
Circ Shock; 1990 Oct; 32(2):153-63. PubMed ID: 2253318
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
14. Tumor necrosis factor (TNF) and endotoxin prime effects of PAF in vivo.
Heuer HO; Letts G; Meade CJ
J Lipid Mediat; 1990; 2 Suppl():S101-8. PubMed ID: 2133276
[TBL] [Abstract][Full Text] [Related]
15. Inhibitor effect of apafant on bronchopulmonary responses to platelet activating factor and to antigen in rats.
Akagi M; Nishioka E; Kanoh R; Tachibana M; Fukuishi N
Arzneimittelforschung; 1997 Dec; 47(12):1364-9. PubMed ID: 9450165
[TBL] [Abstract][Full Text] [Related]
16. The effects of hetrazepine PAF antagonists in preclinical models of asthma.
Heuer HO
Agents Actions Suppl; 1991; 34():229-45. PubMed ID: 1793067
[TBL] [Abstract][Full Text] [Related]
17. Induction of tissue injury and altered cardiovascular performance by platelet-activating factor: relevance to multiple systems organ failure.
Lefer AM
Crit Care Clin; 1989 Apr; 5(2):331-52. PubMed ID: 2650821
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of active anaphylaxis in mice and guinea pigs by the new hetrazepinoic PAF antagonist bepafant (WEB 2170).
Heuer HO
Eur J Pharmacol; 1991 Jun; 199(2):157-63. PubMed ID: 1954975
[TBL] [Abstract][Full Text] [Related]
19. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist.
Rabinovici R; Yue TL; Farhat M; Smith EF; Esser KM; Slivjak M; Feuerstein G
J Pharmacol Exp Ther; 1990 Oct; 255(1):256-63. PubMed ID: 2213560
[TBL] [Abstract][Full Text] [Related]
20. Effect of a platelet-activating factor antagonist on pancreas perfusion after 24 h of ischemia.
Leonhardt U; Exner B; Schrock E; Ritzel U; Nebendahl K; Stöckmann F
Pancreas; 1995 Aug; 11(2):160-4. PubMed ID: 7479673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
